Associations of antibodies against citrullinated peptides with human leukocyte antigen-shared epitope and smoking prior to the development of rheumatoid arthritis

Kokkonen, Heidi; Brink, Mikael; Hansson, Monika; Lassen, Ewa; Mathsson-Alm, Linda; Holmdahl, Rikard; Rönnelid, Johan; Klareskog, Lars; Rantapää-Dahlqvist, Solbritt

doi:10.1186/s13075-015-0638-x

Table 4 Odds ratios (ORs) for disease development in pre-symptomatic individuals for different ACPA and anti-CCP2 in combination with smoking and HLA-SE compared with individuals being ACPA/anti-CCP2 negative, HLA-SE negative, and non-smokers as reference

From: Associations of antibodies against citrullinated peptides with human leukocyte antigen-shared epitope and smoking prior to the development of rheumatoid arthritis

Anti-CCP2/ACPA	Smoking	HLA-SE	Cases/controls	OR (95% CI)
Anti-CCP2/ACPA	(n = 348)	(n = 366)	n/n	OR (95% CI)
Anti-CCP2			345/552^a
−	−	−	31/172	Ref
+	−	−	10/1	55.48 (6.86–448.99)
−	+	−	52/160	1.80 (1.10–2.96)
–	–	+	52/121	2.38 (1.44–3.94)
+	+	–	26/3	48.09 (13.71–168.64)
−	+	+	84/86	5.42 (3.33–8.82)
+	−	+	24/4	33.29 (10.80–102.59)
+	+	+	66/5	73.24 (27.32–196.37)
Anti-CEP-1/Eno5-21			345/541^a
−	−	−	33/163	Ref
+	−	−	8/7	5.65 (1.92–16.64)
−	+	−	58/147	1.95 (1.20–3.16)
−	−	+	56/117	2.36 (1.45–3.86)
+	+	−	20/14	7.05 (3.24–15.37)
−	+	+	96/79	6.00 (3.72–9.68)
+	−	+	20/7	14.11 (5.52–36.08)
+	+	+	54/7	38.10 (15.94–91.11)
Anti-Fibβ36-52			345/541^a
−	−	−	31/161	Ref
+	−	−	10/9	5.77 (2.17–15.36)
−	+	−	56/149	1.95 (1.19–3.19)
−	−	+	54/117	2.40 (1.45–3.96)
+	+	−	22/12	9.52 (4.27–21.22)
−	+	+	97/79	6.38 (3.92–10.37)
+	−	+	22/7	16.32 (6.42–41.51)
+	+	+	53/7	39.32 (16.36–94.51)
Anti-CCP-1/Fil307-324			345/541^a
−	−	−	33/168	Ref
+	−	−	8/2	20.36 (4.14–100.24)
−	+	−	60/157	1.95 (1.21–3.14)
−	−	+	52/120	2.21 (1.35–3.62)
+	+	−	18/4	22.91 (7.28–72.05)
−	+	+	104/80	6.62 (4.12–10.63)
+	−	+	24/4	30.55 (9.94–93.84)
+	+	+	46/6	39.03 (15.42–98.82)
Anti-CEP-1/Eno5-21 + anti-Fibβ36-52 + anti-CCP-1/Fil307-324 ^b			345/541^a
−	−	−	39/170	Ref
+	−	−	1/0	−
−	+	−	72/159	1.97 (1.26–3.08)
−	−	+	66/123	2.33 (1.48–3.70)
+	+	−	6/1	26.15 (3.06–223.50)
−	+	+	122/85	6.26 (4.01)
+	−	+	11/1	47.95 (6.01–382.46)
+	+	+	28/2	61.03 (13.95–267.05)
Anti-CEP-1/Eno5-21 + anti-Fibβ36-52 + anti-CCP-1/Fil307-324 + anti-CCP2 ^c			204/464^a
−	−	−	20/151	Ref
+	−	−	1/0	−
−	+	−	37/133	2.10 (1.16–3.80)
−	−	+	37/105	2.66 (1.46–4.84)
+	+	−	5/0	−
−	+	+	65/72	6.82 (3.84–12.11)
+	−	+	11/1	83.05 (10.17–677.91)
+	+	+	28/2	105.70 (23.39–477.74)

^aTotal number included in analysis. ^bPositive = positive for all of the three antibodies and negative = any of the antibodies negative. ^cPositive = all four antibodies positive and negative = all four antibodies negative. anti-CCP2=anti-cyclic citrullinated peptide antibodies, ACPA= anti citrullinated peptide/protein antibodies, HLA-SE= HLA shared epitope, OR= odds ratio, CI= confidence intervals, anti CEP-1/Eno5-21= antibodies against alpha-Enolase, anti-citC1359-369= antibodies against collagen type II aa 359-369 with two citrulline residues, anti- Fibα580-600=antibodies against fibrinogen (Fib) Fibα580-600, anti-Fibα561-583= antibodies against Fibα561-583, anti- Fibβ62-81a(72)=antibodies against Fibβ62-81a(72), anti-Fibβ62-81b(74)= antibodies against Fibβ62-81b(74), anti-Fibβ36-52= antibodies against Fibβ36-52, anti- CCP-1/Fil307-324= antibodies against filaggrin, anti- Vim60-75= antibodies against vimentin (Vim)60-75, anti-Vim2-17= antibodies against Vim 2-17.

Back to article page

ISSN: 1478-6362

Contact us

General enquiries: journalsubmissions@springernature.com

Arthritis Research & Therapy

Contact us